Description: Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.
Home Page: www.senseibio.com
SNSE Technical Analysis
451 D Street
Rockville,
MD
02210
United States
Phone:
240 243 8000
Officers
| Name | Title |
|---|---|
| Mr. John K. Celebi M.B.A., MBA | Pres, CEO & Director |
| Ms. Erin Colgan | Chief Financial Officer |
| Dr. Steven A. Fuller | Chief Biopharmaceuticals Devel. Officer |
| Dr. Edward Van der Horst Ph.D. | Chief Scientific Officer |
| Ms. Lora Pike | VP of Investor Relations & Communications |
| Mr. Christopher Gerry J.D. | VP & Gen. Counsel |
| Ms. Elisabeth Colunio | VP of HR |
| Mr. Patrick Stephen Gallagher M.B.A., M.P.H. | Chief Bus. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4258 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-02-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 44 |